Lung cancer alters the hydrolysis of nucleotides and nucleosides in platelets

Biomedicine and Pharmacotherapy

Volumn 66, Issue 1, 2012, Pages 40-45

  Zanini, Daniela ^a   Schmatz, Roberta ^a   Pimentel, Victor Camera ^a   Gutierres, Jessié Martins ^a   Maldonado, Paula Acosta ^a   Thomé, Gustavo Roberto ^a   Cardoso, Andréia Machado ^a   Stefanello, Naiara ^a   Oliveira, Liliane ^a   Chiesa, Juarez ^a   Leal, Daniela Bitencourt Rosa ^a   Morsch, Vera Maria ^a   Schetinger, Maria Rosa Chitolina ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

5' nucleotidase; Adenosine deaminase; Ectonucleotide pyrophosphatase phosphodiesterase; Lung neoplasm; NTPDase

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE DEAMINASE; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; AUTOTAXIN; CD39 ANTIGEN; CISPLATIN; GEMCITABINE; NUCLEOSIDE; NUCLEOTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYDROLYSIS; LUNG CANCER; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROLYSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NUCLEOSIDES; NUCLEOTIDES; PLATELET AGGREGATION;

EID: 84856645201     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.09.003     Document Type: Article

References (36)

1. Guerra M.R., Gallo C.V.M., Mendonça G.A.S. Riscos de câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Rev Bras Cancerol 2005, 51:227-234.
2. Wang Y., Yang H., Li L., Wang H., Zhang C., Yin G., et al. Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis. Eur J Cancer 2010, 46:758-764.
3. Uehara C, Jamnik S, Santoro IL, Câncer de pulmão, Medicina. Ribeirão Preto, 1998.
4. Burnstock G. Potential therapeutic targets in the rapidly expanding field of purinergic signaling. Clin Med 2002, 2:45-53.
5. Schetinger M.R.C., Morsch V.M., Bonan C.D., Wyse A.T.S. NTPDase and 5'-nucleotidase activities in physiological and disease conditions: new perspectives for human health. Biofactors 2007, 31:77-98.
6. Donati M.B., Falanga A. Pathogenetic mechanisms of thrombosis in malignancy. Acta Haematol 2001, 106:18-24.
7. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., Islam N., Pinsky D.J., Sesti C., et al. Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1). J Thromb Haemost 2003, 1:2497-2509.
8. Rozalski M., Nocul M., Watala C. Adenosina diphosphate receptors on blood platelets - potential new targets for antiplatelet therapy. Acta Biochim Pol 2005, 52:411-415.
9. Bours M.J.L., Swennen E.L.R., Di Virgilio F., Cronstein B.N., Gagnelie P.C. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Therap 2006, 112:358-404.
10. Goding J.W., Grobbem B., Slegers H. Physiological and patophysiological functions of the ectonucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta 2003, 1638:1-19.
11. Fürstenau C.R., Trentin D.S., Barreto-Chaves M.L.M., Sarkis J.J.F. Ectonucleotide pyrophosphatase/phosphodiesterase as a part of multiple system for nucleotide hydrolysis by platelets from rats: kinetic characterization and biochemical properties. Platelets 2006, 17:84-91.
12. Barankiewicz J., Danks A.M., Abushanab E., Makings L., Wiemann T., Wallis R.A., et al. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. J Pharmacol Exp Ther 1997, 283:1230-1238.
13. Anfossi G., Russo I., Massucco P., Mattiello L., Cavalot F., Balbo A., et al. Adenosine increases human platelet levels of cGMP through role in this antiaggregating effect. Thromb Res 2002, 105:71-78.
14. Fischer D., Van der Weyden M.B., Snyderman R., Kelley W.N. A role for adenosine deaminase in monocyte maturation. J Clin Invest 1976, 58:399-407.
15. Spychala J. Tumor promoting functions of adenosine. Pharmacol Therap 2000, 87:161-173.
16. Gessi K., Varani S., Merighi S. Adenosine and lymphocyte regulation. Purinergic Signalling 2007, 3:109-116.
17. Blackburn M.R., Kellems R.E. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol 2005, 86:1-41.
18. Yegutkin G.G. Nucleotide-and nucleoside-converting ectoenzymes: important modulators of purinergic signalling cascade. Biochim Biophys Acta (BBA) - Mol Cell Res 2008, 1758:673-694.
19. Pilla C., Emanuelli T., Frasetto S.S., Battastini A.M.O., Dias R.D., Sarkis J.J.F. ATP diphosphohydrolase activity (apyrase, EC 3.6.1.5) in human blood platelets. Platelets 1996, 7:225-230.
20. Chan K., Delfert K., Junguer K.D. A direct colorimetric assay for Ca2+-ATPase activity. Anal Biochem 1986, 157:375-380.
21. Guisti G., Galanti B. Colorimetric method. Methods of enzymatic analysis 1984, 315-323. Verlag Chemie, Weinheim. H.U. Bergmeyer (Ed.).
22. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:218-254.
23. De Cos Escuín J.S. El cáncer depulmón en España. Epidemiología, supervivencia y tratamiento actuales. Arch Bronconeumol 2009, 45:341-348.
24. Robson S.C., Sévigny J., Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal 2006, 2:409-430.
25. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
26. Cote M.L., Chen W., Smith D.W., Benhamou S., Bouchardy C., Butkiewicz D., et al. Meta-and pooled analysis of GSTP1 polymorphism and lung cancer: a HuGE-GSEC review. Am J Epidemiol 2009, 169:802-814.
27. Enjyoji K., Sóevigny J., Lin Y., Frenette P.S., Christie P.D., Am Esch I.I., et al. Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nature Med 1999, 5:1010-1017.
28. Marcus A.J., Broekman M.J., Drosopoulos J.H.F., Islam N., Pinsky D.J., Gayle R., et al. Thromboregulation by endothelial cells: significance for occlusive vascular diseases. Arterioscler Thromb Vasc Biol 2001, 21:178-182.
29. Birk A.V., Bubman D., Broekman M.J., Robertson H.D., Drosopoulos J.H., Marcus A.J., et al. Role of a novel soluble nucleotide phosphohydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biology. J Lab Clin Med 2002, 139:116-124.
30. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005, 6:401-410.
31. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol 2004, 50:187-196.
32. Merighi S., Mirandola P., Varani K., Gessi S., Leung E., Baraldi G.P., et al. A glance at adenosine receptors: novel target for antitumor therapy. Pharmacol Ther 2003, 100:31-48.
33. Munson L., Upadhyaya N.B., Meter S.V. Platelet-derived growth factor promotes endometrial epithelial cell proliferation. Am J Obstet Gynecol 1995, 173:1820-1825.
34. Maldonado P.A., Negrini L.A., Ethur J.S., Oliveira L., Corrêa M.C., Becker L.V., et al. Nucleotide degrading enzymes in platelets from uterine cervical neoplasia patients treated with conization or radiotherapy. Biomed Pharmacother 2010, 64:499-504.
35. Hunsuckera S.A., Mitchella B.S., Spychala J. The 5'-nucleotidases as regulators of nucleotide and drug metabolism. Pharmacol Ther 2005, 107:1-30.
36. Spychala J., Kitajewski J. WnT and β-catenin signaling target the expression of ecto-5'-nucleotidase and increase extracellular adenosine generation. Exp Cell Res 2004, 296:99-108.